| Linda Wendell, MD | |
|
593 Eddy St, Apc 7 Nicu, Providence, RI 02903-4923 | |
| (401) 444-2734 | |
| (401) 444-8555 |
| Full Name | Linda Wendell |
|---|---|
| Gender | Female |
| Speciality | Neurology |
| Experience | 20 Years |
| Location | 593 Eddy St, Providence, Rhode Island |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1215154430 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084N0400X | Psychiatry & Neurology - Neurology | MD13334 (Rhode Island) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mount Auburn Hospital | Cambridge, MA | Hospital |
| Beth Israel Deaconess Medical Center | Boston, MA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mt Auburn Professional Services | 6103725031 | 256 |
News Archive
Approximately half to three quarters of adults ages 18 to 65 experienced headache last year, making headache disorders one of the most prevalent but under-treated health problems in the world, according to a report released Tuesday by the WHO, Xinhua reports.
Emergent BioSolutions Inc. today announced that it has been awarded five separate grants under the Qualifying Therapeutic Discovery Project (QTDP) Program to support continued development of its therapeutic programs in oncology and autoimmunity. The grants, with a total value of over $1.2 million, will fund Emergent's TRU-016 Small Modular ImmunoPharmaceutical (SMIP™), DRACO anti-CD3 SMIP, X1 TNF-based SCORPION™, X2 CTLA4-based SCORPION, and T-Scorps-based SCORPION therapeutic programs.
Less than half of individuals with peripheral artery disease, which is a narrowing of arteries to the limbs, stomach and head, are treated with appropriate medications and lifestyle counseling. These findings highlight the need to improve the quality of care for this high-risk group of individuals.
3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced it has entered into an exclusive licensing deal with PharmAbcine Inc. for the development, manufacturing and marketing of DIG-KT, a bi-specific monoclonal antibody ("mAb") targeting both VEGFR2/KDR and Tie-2 pathways for cancer in the territory of Greater China (including mainland China, Taiwan, Hong Kong and Macau) and Korea.
The better informed people are about cancer clinical trials, the more likely they are overall to consider participating in a trial, according to a UC Davis study published in today's issue of the Journal of Clinical Oncology. However, knowing about cancer clinical trials does not appear to increase participation among black and Asian Americans.
› Verified 8 days ago
| Entity Name | Mt Auburn Professional Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1992750996 PECOS PAC ID: 6103725031 Enrollment ID: O20040527001374 |
News Archive
Approximately half to three quarters of adults ages 18 to 65 experienced headache last year, making headache disorders one of the most prevalent but under-treated health problems in the world, according to a report released Tuesday by the WHO, Xinhua reports.
Emergent BioSolutions Inc. today announced that it has been awarded five separate grants under the Qualifying Therapeutic Discovery Project (QTDP) Program to support continued development of its therapeutic programs in oncology and autoimmunity. The grants, with a total value of over $1.2 million, will fund Emergent's TRU-016 Small Modular ImmunoPharmaceutical (SMIP™), DRACO anti-CD3 SMIP, X1 TNF-based SCORPION™, X2 CTLA4-based SCORPION, and T-Scorps-based SCORPION therapeutic programs.
Less than half of individuals with peripheral artery disease, which is a narrowing of arteries to the limbs, stomach and head, are treated with appropriate medications and lifestyle counseling. These findings highlight the need to improve the quality of care for this high-risk group of individuals.
3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced it has entered into an exclusive licensing deal with PharmAbcine Inc. for the development, manufacturing and marketing of DIG-KT, a bi-specific monoclonal antibody ("mAb") targeting both VEGFR2/KDR and Tie-2 pathways for cancer in the territory of Greater China (including mainland China, Taiwan, Hong Kong and Macau) and Korea.
The better informed people are about cancer clinical trials, the more likely they are overall to consider participating in a trial, according to a UC Davis study published in today's issue of the Journal of Clinical Oncology. However, knowing about cancer clinical trials does not appear to increase participation among black and Asian Americans.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Linda Wendell, MD 117 Ellenfield St Ste 101, Providence, RI 02905-4513 Ph: (401) 444-6779 | Linda Wendell, MD 593 Eddy St, Apc 7 Nicu, Providence, RI 02903-4923 Ph: (401) 444-2734 |
News Archive
Approximately half to three quarters of adults ages 18 to 65 experienced headache last year, making headache disorders one of the most prevalent but under-treated health problems in the world, according to a report released Tuesday by the WHO, Xinhua reports.
Emergent BioSolutions Inc. today announced that it has been awarded five separate grants under the Qualifying Therapeutic Discovery Project (QTDP) Program to support continued development of its therapeutic programs in oncology and autoimmunity. The grants, with a total value of over $1.2 million, will fund Emergent's TRU-016 Small Modular ImmunoPharmaceutical (SMIP™), DRACO anti-CD3 SMIP, X1 TNF-based SCORPION™, X2 CTLA4-based SCORPION, and T-Scorps-based SCORPION therapeutic programs.
Less than half of individuals with peripheral artery disease, which is a narrowing of arteries to the limbs, stomach and head, are treated with appropriate medications and lifestyle counseling. These findings highlight the need to improve the quality of care for this high-risk group of individuals.
3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced it has entered into an exclusive licensing deal with PharmAbcine Inc. for the development, manufacturing and marketing of DIG-KT, a bi-specific monoclonal antibody ("mAb") targeting both VEGFR2/KDR and Tie-2 pathways for cancer in the territory of Greater China (including mainland China, Taiwan, Hong Kong and Macau) and Korea.
The better informed people are about cancer clinical trials, the more likely they are overall to consider participating in a trial, according to a UC Davis study published in today's issue of the Journal of Clinical Oncology. However, knowing about cancer clinical trials does not appear to increase participation among black and Asian Americans.
› Verified 8 days ago
Dr. Dana Siperstein, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 167 Point St, Providence, RI 02903 Phone: 401-793-8808 Fax: 401-793-8851 | |
Giuseppe Salvatore D'amelio Iv, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 167 Point St, Providence, RI 02903 Phone: 401-793-8808 | |
Eugenie Atallah, Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 593 Eddy St, Providence, RI 02903 Phone: 401-606-2645 Fax: 401-606-4386 | |
Dr. Luisa Skoble, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 593 Eddy St, Providence, RI 02903 Phone: 401-444-5448 Fax: 401-444-6119 | |
Arnaldo A Berges, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 593 Eddy St, Jane Brown 5s, Providence, RI 02903 Phone: 401-444-5448 Fax: 401-444-6119 | |
Sharath Ponnappa Puttichanda, Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 345 Blackstone Blvd, Providence, RI 02906 Phone: 401-455-6346 Fax: 401-455-6532 | |
Loreen Phyllis Carol Pirnie, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 593 Eddy St, Providence, RI 02903 Phone: 401-444-5448 |